Qyuns Therapeutics Buys Back 174,400 H-Shares, Expands Treasury Stock to 2.88 Million Shares

Bulletin Express

06/01

Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share-repurchase transaction conducted on 1 June 2026 under its Hong Kong Stock Exchange mandate approved on 29 May 2026.

• Transaction details – Volume repurchased: 174,400 H-shares, now held as treasury stock. – Price range: HKD 15.66 to HKD 16.54 per share, with a volume-weighted average of HKD 16.14. – Aggregate consideration: HKD 2.81 million.

• Capital structure impact – Issued shares outstanding (excluding treasury shares) decreased to 224.19 million from 224.36 million, a reduction of 0.08%. – Treasury shares rose to 2.88 million from 2.71 million. – Total issued shares remained unchanged at 227.07 million.

• Repurchase capacity – The current mandate authorises buybacks of up to 22.44 million shares; the latest transaction utilises 0.78% of that limit. – A 30-day moratorium on new share issues or treasury-share disposals runs through 1 July 2026, in line with HKEX Rule 10.06(3).

The company confirmed that the repurchase complied with Main Board requirements and that no material changes have been made to the explanatory statement filed on 8 May 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1100751279"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100751279\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100751279?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100751279","market":"us","top_or_hot":-1,"title":"Qyuns Therapeutics Buys Back 174,400 H-Shares, Expands Treasury Stock to 2.88 Million Shares","media":"Bulletin Express","content":"<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share-repurchase transaction conducted on 1 June 2026 under its Hong Kong Stock Exchange mandate approved on 29 May 2026.</p>\n<p>• Transaction details  \n  – Volume repurchased: 174,400 H-shares, now held as treasury stock.  \n  – Price range: HKD 15.66 to HKD 16.54 per share, with a volume-weighted average of HKD 16.14.  \n  – Aggregate consideration: HKD 2.81 million.</p>\n<p>• Capital structure impact  \n  – Issued shares outstanding (excluding treasury shares) decreased to 224.19 million from 224.36 million, a reduction of 0.08%.  \n  – Treasury shares rose to 2.88 million from 2.71 million.  \n  – Total issued shares remained unchanged at 227.07 million.</p>\n<p>• Repurchase capacity  \n  – The current mandate authorises buybacks of up to 22.44 million shares; the latest transaction utilises 0.78% of that limit.  \n  – A 30-day moratorium on new share issues or treasury-share disposals runs through 1 July 2026, in line with HKEX Rule 10.06(3).</p>\n<p>The company confirmed that the repurchase complied with Main Board requirements and that no material changes have been made to the explanatory statement filed on 8 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics Buys Back 174,400 H-Shares, Expands Treasury Stock to 2.88 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics Buys Back 174,400 H-Shares, Expands Treasury Stock to 2.88 Million Shares\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-06-01 21:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share-repurchase transaction conducted on 1 June 2026 under its Hong Kong Stock Exchange mandate approved on 29 May 2026.</p>\n<p>• Transaction details  \n  – Volume repurchased: 174,400 H-shares, now held as treasury stock.  \n  – Price range: HKD 15.66 to HKD 16.54 per share, with a volume-weighted average of HKD 16.14.  \n  – Aggregate consideration: HKD 2.81 million.</p>\n<p>• Capital structure impact  \n  – Issued shares outstanding (excluding treasury shares) decreased to 224.19 million from 224.36 million, a reduction of 0.08%.  \n  – Treasury shares rose to 2.88 million from 2.71 million.  \n  – Total issued shares remained unchanged at 227.07 million.</p>\n<p>• Repurchase capacity  \n  – The current mandate authorises buybacks of up to 22.44 million shares; the latest transaction utilises 0.78% of that limit.  \n  – A 30-day moratorium on new share issues or treasury-share disposals runs through 1 July 2026, in line with HKEX Rule 10.06(3).</p>\n<p>The company confirmed that the repurchase complied with Main Board requirements and that no material changes have been made to the explanatory statement filed on 8 May 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1100751279","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100751279","pubTimestamp":1780321441,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share-repurchase transaction conducted on 1 June 2026 under its Hong Kong Stock Exchange mandate approved on 29 May 2026. • Transaction details...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"Qyuns Therapeutics回购17.44万股H股，库存股扩大至288万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share-repurchase transaction conducted on 1 June 2026 under its Hong Kong Stock Exchange mandate approved on 29 May 2026.\n• Transaction details  \n  – Volume repurchased: 174,400 H-shares, now held as treasury stock.  \n  – Price range: HKD 15.66 to HKD 16.54 per share, with a volume-weighted average of HKD 16.14.  \n  – Aggregate consideration: HKD 2.81 million.\n• Capital structure impact  \n  – Issued shares outstanding (excluding treasury shares) decreased to 224.19 million from 224.36 million, a reduction of 0.08%.  \n  – Treasury shares rose to 2.88 million from 2.71 million.  \n  – Total issued shares remained unchanged at 227.07 million.\n• Repurchase capacity  \n  – The current mandate authorises buybacks of up to 22.44 million shares; the latest transaction utilises 0.78% of that limit.  \n  – A 30-day moratorium on new share issues or treasury-share disposals runs through 1 July 2026, in line with HKEX Rule 10.06(3).\nThe company confirmed that the repurchase complied with Main Board requirements and that no material changes have been made to the explanatory statement filed on 8 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}